Artelo Biosciences surges after obesity patent filing puts ART27.13 in focus

Artelo Biosciences (ARTL) is up 207.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst is today’s announcement that the company filed a new provisional patent application for ART27.13 in obesity, including use alongside GLP-1 drugs. The release also expanded on recent mouse data showing semaglutide-like weight loss as a standalone therapy and greater effects in combination, which appears to have reignited speculative interest in the program. A secondary factor could be the stock’s small post-split share count, which can make moves much sharper when volume spikes.

Details:

The company said on September 23 it filed a provisional patent application covering ART27.13 for obesity as both a monotherapy and in combination with GLP-1 receptor agonists.

The announcement highlighted prior nonclinical findings in obese mice: about 20% weight loss over four weeks with ART27.13 alone and about 40% weight loss when combined with semaglutide.

Additional findings disclosed today included stronger appetite suppression versus semaglutide alone, improved oral glucose tolerance, and higher bone mineral density in the combination group.

This could be because the setup was already primed for volatility after the company’s 1-for-9 reverse split, which left roughly 547,774 shares outstanding immediately afterward.

Sources:

Artelo Biosciences, SEC, Stock Titan

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ARTL Hedge Fund Activity

We have seen 7 institutional investors add shares of $ARTL stock to their portfolio, and 8 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JANE STREET GROUP, LLC added 53,262 shares (+407.2%) to their portfolio in Q2 2026, for an estimated $59,653
TWO SIGMA INVESTMENTS, LP removed 20,669 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $156,671
VIRTU FINANCIAL LLC removed 16,865 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $127,836
GEODE CAPITAL MANAGEMENT, LLC added 13,864 shares (+inf%) to their portfolio in Q2 2026, for an estimated $15,527
KATHMERE CAPITAL MANAGEMENT, LLC removed 13,250 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $14,840
STONEX GROUP INC. added 12,400 shares (+inf%) to their portfolio in Q2 2026, for an estimated $13,888
TOWER RESEARCH CAPITAL LLC (TRC) added 5,609 shares (+198.5%) to their portfolio in Q2 2026, for an estimated $6,282

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.